Introduction
Global contract development and manufacturing organization (CDMO) Lonza has announced a significant expansion of its Highly Potent Active Pharmaceutical Ingredient (HPAPI) and payload-linker manufacturing capabilities at its Visp, Switzerland facility. The investment is aimed at meeting the increasing global demand for Antibody-Drug Conjugates (ADCs), one of the fastest-growing areas in cancer treatment.
The expanded facility is expected to become operational in 2028 and will strengthen Lonza’s end-to-end ADC manufacturing services for pharmaceutical and biotechnology companies worldwide.
Highlights at a Glance
| Particular | Details |
|---|---|
| Company | Lonza |
| Facility Location | Visp, Switzerland |
| Investment Focus | HPAPI & ADC Payload-Linker Manufacturing |
| Industry | Contract Development and Manufacturing Organization (CDMO) |
| Purpose | Expand capacity to meet rising ADC demand |
| Expected Operational Year | 2028 |
| Target Customers | Pharmaceutical & Biotechnology Companies |
| Key Applications | Clinical and Commercial ADC Manufacturing |
Why is Lonza Expanding?
The global oncology market is witnessing rapid adoption of Antibody-Drug Conjugates (ADCs) due to their ability to deliver highly potent drugs directly to cancer cells while minimizing damage to healthy tissues.
As more ADC therapies enter clinical trials and receive regulatory approvals, demand for:
- Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
- Complex Payload-Linkers
- Specialized manufacturing facilities
- Advanced analytical capabilities
continues to rise.
To address this demand, Lonza is investing in expanding its manufacturing infrastructure in Switzerland.
What Will the Expansion Include?
The new investment will add several advanced manufacturing capabilities, including:
Commercial-Scale HPAPI Manufacturing
The facility will manufacture highly potent active pharmaceutical ingredients required for modern ADC therapies.
Payload-Linker Manufacturing
Dedicated production units will manufacture complex payload-linkers that connect antibodies with potent cytotoxic drugs.
Purification Facilities
New purification suites will improve product quality, efficiency, and manufacturing reliability.
Analytical Laboratories
Advanced analytical labs will support:
- Product characterization
- Quality testing
- Regulatory compliance
- Stability studies
Process Development Laboratories
These laboratories will help optimize manufacturing processes for both clinical and commercial production.
Flexible Manufacturing Design
Lonza has designed the upgraded facility with future expansion in mind.
Key features include:
- Multipurpose GMP manufacturing suites
- Flexible production lines
- Easy addition of new manufacturing suites
- Scale-out capability based on future customer demand
This allows the company to rapidly increase production capacity as the ADC market continues to expand.
Integration with Existing ADC Network
The Visp expansion will complement Lonza’s existing ADC ecosystem located in Visp and Stein, Switzerland.
Current capabilities include:
- Monoclonal antibody manufacturing
- Bioconjugation services
- Drug product manufacturing
- Quality control testing
- End-to-end ADC development support
The integrated model enables customers to work with a single manufacturing partner from early-stage development through commercial production.
Timeline
| Milestone | Expected Timeline |
|---|---|
| Expansion Announcement | 2026 |
| Facility Construction & Development | Ongoing |
| Commercial Operations Begin | 2028 |
Statement from Lonza
Christian Seufert, Head of Advanced Synthesis at Lonza, stated that the rapid expansion of the ADC market is increasing demand for more sophisticated payload-linkers and advanced HPAPI manufacturing technologies.
He emphasized that the investment demonstrates Lonza’s commitment to strengthening its integrated ADC platform and supporting customers throughout the complete product lifecycle—from early research to commercial manufacturing.
Why This Expansion Matters
The investment is expected to provide several benefits:
- Increased global manufacturing capacity for ADCs
- Faster commercialization of targeted cancer therapies
- Improved supply chain reliability
- Enhanced support for biotech startups and pharmaceutical companies
- Greater flexibility for future ADC manufacturing demand
About Antibody-Drug Conjugates (ADCs)
Antibody-Drug Conjugates are targeted cancer therapies that combine:
- A monoclonal antibody
- A highly potent cytotoxic drug (payload)
- A chemical linker connecting both components
This technology allows the drug to specifically target cancer cells while reducing damage to healthy tissues, making ADCs one of the most promising innovations in oncology.
Conclusion
Lonza’s planned expansion of its HPAPI and payload-linker manufacturing facility in Visp, Switzerland, represents a major step toward supporting the rapidly growing ADC industry. By investing in advanced manufacturing infrastructure, analytical laboratories, and flexible production capabilities, the company aims to provide comprehensive support for both clinical and commercial ADC programs. As demand for targeted cancer therapies continues to rise, this expansion is expected to play an important role in accelerating the development and global availability of next-generation oncology treatments.
Recommended Products
